Frontierby eninvs

Language: EN · RU

← Region

JOHNSON & JOHNSON (JNJ) USD

At a glance: strengths & risks
✓Revenue growing (+6%)✓Profit growing (+91%)✓Margins improving (32%→37%)✓Low leverage (0.8x EBITDA)✗Pricier than own history (EV/EBITDA 20.9 vs avg 15.0)

Sector: Health care

US_JNJ

Price chart

259.27 USDDay 1.42%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
259.27 USD · 1.42%
Market cap
624.3 bn USD

Growth

Δ revenue y/y
6.6%
Δ EBITDA y/y
-14.9%

Multiples

P/E (LTM)
29.7x
3y avg: 18.0x
P/B (FY)
7.7x
P/E (ann.)
28.2x
EV/EBITDA (LTM)
20.9x
3y avg: 15.0x
EV/EBITDA (ann.)
22.9x

Cash return

Dividend yield
2.0%
FCF yield (LTM)
2.0%

Value creation

fundamental value/yr, % of market cap
Value created / year
-13.8%
↓ details

Liquidity

Daily turnover (US listing)
2.1 bln USD

Shares: yahoo_fundamentals_timeseries/JNJ

Financial results

Monetary columns are in B USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueB USDOperating profitB USDD&AB USDEBITDAB USDNet profitB USDOperating CFB USDCapex + M&AB USDAssetsB USDEquityB USDROE (annualized)Net debtB USDSource
2026-06-30Q2 2026 (3M)PARTIAL25.3
y/y 6.6%
7.2
y/y 10.5%
—
y/y —
7.2
y/y -14.9%
5.5
y/y -0.1%
———
y/y —
—
y/y —
———
2026-03-29Q1 2026 (3M)OK24.1
y/y 9.9%
6.0
y/y -25.2%
2.0
y/y 13.1%
8.0
y/y -18.3%
5.2
y/y -52.4%
2.5-1.0200.9
y/y 3.7%
81.2
y/y 3.9%
25.7%32.9Link
2025-12-31Q4 2025 (3M)OK24.6
y/y 9.1%
5.0
y/y 27.8%
2.0
y/y 6.1%
7.0
y/y 20.6%
5.1
y/y 49.1%
7.320.5199.2
y/y 10.6%
81.5
y/y 14.1%
25.1%21.7Link
2025-12-28Q4 2025 (3M)OK24.6
y/y 9.1%
5.0
y/y 27.8%
2.0
y/y 6.1%
7.0
y/y 20.6%
5.1
y/y 49.1%
7.3-19.4199.2
y/y 10.6%
81.5
y/y 14.1%
33.3%27.8Link
2025-09-28Q3 2025 (3M)OK24.0
y/y 6.8%
7.5
y/y 124.5%
1.8
y/y -3.7%
9.3
y/y 78.8%
5.2
y/y 91.2%
9.2-1.2192.8
y/y 8.1%
79.3
y/y 13.0%
8.7%27.2Link
2025-06-29Q2 2025 (3M)OK23.7
y/y 5.8%
6.5
y/y 12.9%
1.9
y/y 9.0%
8.4
y/y 12.0%
5.5
y/y 18.2%
3.9-1.0193.4
y/y 6.8%
78.5
y/y 9.7%
28.3%31.9Link
2025-03-30Q1 2025 (3M)OK21.9
y/y 2.4%
8.0
y/y 1.7%
1.8
y/y -2.4%
9.8
y/y 0.9%
11.0
y/y 237.9%
4.2-0.8193.7
y/y 12.6%
78.1
y/y 11.6%
58.8%13.5Link
2024-12-31Q4 2024 (3M)OK22.5
y/y —
3.9
y/y —
1.9
y/y —
5.8
y/y —
3.4
y/y —
7.018.0180.1
y/y —
71.5
y/y —
19.2%8.3Link
2024-12-29Q4 2024 (3M)OK22.5
y/y 5.3%
3.9
y/y -19.5%
1.9
y/y 2.9%
5.8
y/y -13.3%
3.4
y/y -15.3%
7.0-1.6180.1
y/y 7.5%
71.5
y/y 3.9%
19.9%12.1Link
2024-09-29Q3 2024 (3M)OK22.5
y/y 5.2%
3.3
y/y -36.0%
1.8
y/y 0.9%
5.2
y/y -26.4%
2.7
y/y -89.6%
8.0-1.4178.3
y/y 7.4%
70.2
y/y -1.5%
5.1%15.5Link
2024-06-30Q2 2024 (3M)OK22.4
y/y 4.3%
5.7
y/y -8.8%
1.8
y/y -7.9%
7.5
y/y -8.6%
4.7
y/y -8.9%
5.6-14.0181.1
y/y -5.5%
71.5
y/y -4.8%
26.5%16.0Link
2024-03-31Q1 2024 (3M)OK21.4
y/y 2.3%
7.9
y/y —
1.8
y/y -3.5%
9.7
y/y 1534.4%
3.3
y/y —
3.7-2.6172.0
y/y -12.2%
70.0
y/y -1.2%
18.8%7.4Link
2023-12-31Q4 2023 (3M)OK21.4
y/y —
4.8
y/y —
1.8
y/y —
6.7
y/y —
4.0
y/y —
7.9-1.6167.6
y/y —
68.8
y/y —
50.2%6.5Link
2023-10-01Q4 2023 (3M)OK21.4
y/y —
5.2
y/y —
1.8
y/y —
7.0
y/y —
26.0
y/y —
7.5-1.0166.1
y/y —
71.2
y/y —
47.4%6.4Link
2023-07-02Q3 2023 (3M)OK21.5
y/y —
6.3
y/y —
1.9
y/y —
8.2
y/y —
5.1
y/y —
4.2-1.1191.7
y/y —
75.1
y/y —
28.2%17.1Link
2023-04-02Q2 2023 (3M)OK20.9
y/y —
-1.3
y/y —
1.9
y/y —
0.6
y/y —
-0.1
y/y —
3.3-0.9196.0
y/y —
70.9
y/y —
-0.4%28.3Link
2023-01-01FY 2023 (12M)OK80.0
y/y —
19.4
y/y —
7.0
y/y —
26.3
y/y —
17.9
y/y —
21.2-21.7187.4
y/y —
76.8
y/y —
—17.4Link

Revenue & EBITDA

RevenueEBITDA

Quarterly values ($ mln)

010 00020 00030 0002024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Year-over-year change

-25%0%25%50%75%2024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Cash flow

FCF ($ mln)

-15 000-10 000-5 00005 00010 0002024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Net debt / cash ($ mln)

010 00020 00030 0002024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: -13.8%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-06-30 vs 2025-06-29)
= (7 174 − 8 434) × 4.38
-5 518
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (624 306 + 32 936) ÷ 31 415
20.9x
3. Target multiple
(Current EV/EBITDA + 12) ÷ 2
= (20.9 + 12) ÷ 2
16.5x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= -1 055 + 6 263 + 5 930 − 0
11 138
4b. Share dilution (at market, LTM)
Share-count growth over the year × Market cap
= 1.1% × 624 306
−6 736
5. Value created per year
(EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap
= (-5 518 × 16.5 + 11 138 − 6 736) ÷ 624 306
-13.8%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

  • FCF (LTM) approximated by latest FY
  • share-count dilution 1.1%/yr (valued at market: -6736)

Revenue growth & acceleration

Growth steady →
Last-year revenue growth +6% vs +4% the year before — a +1.7 pp move. 3-year CAGR +6%.
revenue growth by year: 2023 +8% · 2024 +4% · 2025 +6%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

EV/EBITDA — daily history

Current 20.3x · 3-year average 19.0x

EV/EBITDA3-year 75th pct

Dividends

Paid (completed)

DatePer shareDetailsStatusSource
2026-05-261.34 USDEx-dividend: 1.34 USD per sharePaidYahoo Finance (ex-div)
2026-02-241.3 USDEx-dividend: 1.3 USD per sharePaidYahoo Finance (ex-div)
2025-11-251.3 USDEx-dividend: 1.3 USD per sharePaidYahoo Finance (ex-div)
2025-08-261.3 USDEx-dividend: 1.3 USD per sharePaidYahoo Finance (ex-div)
2025-05-271.3 USDEx-dividend: 1.3 USD per sharePaidYahoo Finance (ex-div)
2025-02-181.24 USDEx-dividend: 1.24 USD per sharePaidYahoo Finance (ex-div)
2024-11-261.24 USDEx-dividend: 1.24 USD per sharePaidYahoo Finance (ex-div)
2024-08-271.24 USDEx-dividend: 1.24 USD per sharePaidYahoo Finance (ex-div)
2024-05-201.24 USDEx-dividend: 1.24 USD per sharePaidYahoo Finance (ex-div)
2024-02-161.19 USDEx-dividend: 1.19 USD per sharePaidYahoo Finance (ex-div)
2023-11-201.19 USDEx-dividend: 1.19 USD per sharePaidYahoo Finance (ex-div)
2023-08-251.19 USDEx-dividend: 1.19 USD per sharePaidYahoo Finance (ex-div)
2023-05-221.19 USDEx-dividend: 1.19 USD per sharePaidYahoo Finance (ex-div)
2023-02-171.13 USDEx-dividend: 1.13 USD per sharePaidYahoo Finance (ex-div)
2022-11-211.13 USDEx-dividend: 1.13 USD per sharePaidYahoo Finance (ex-div)
2022-08-221.13 USDEx-dividend: 1.13 USD per sharePaidYahoo Finance (ex-div)
2022-05-231.13 USDEx-dividend: 1.13 USD per sharePaidYahoo Finance (ex-div)
2022-02-181.06 USDEx-dividend: 1.06 USD per sharePaidYahoo Finance (ex-div)
2021-11-221.06 USDEx-dividend: 1.06 USD per sharePaidYahoo Finance (ex-div)
2021-08-231.06 USDEx-dividend: 1.06 USD per sharePaidYahoo Finance (ex-div)

KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of JOHNSON & JOHNSON (JNJ) — from primary filings.

Healthcare conglomerate—prescription medicines, medical devices, and consumer health products.

Frequently asked questions

What is JOHNSON & JOHNSON (JNJ)'s P/E ratio?
JOHNSON & JOHNSON (JNJ) trades at a P/E of 29.7x (price to trailing 12-month earnings).
What is JOHNSON & JOHNSON (JNJ)'s EV/EBITDA?
JOHNSON & JOHNSON (JNJ) trades at 20.9x EV/EBITDA.
What is JOHNSON & JOHNSON (JNJ)'s P/B ratio?
JOHNSON & JOHNSON (JNJ) trades at a P/B of 7.7x.
What is JOHNSON & JOHNSON (JNJ)'s dividend yield?
JOHNSON & JOHNSON (JNJ)'s trailing 12-month dividend yield is 2.0%.
What is JOHNSON & JOHNSON (JNJ)'s return on equity (ROE)?
JOHNSON & JOHNSON (JNJ)'s ROE is 25.7%.
What is JOHNSON & JOHNSON (JNJ)'s market capitalization?
JOHNSON & JOHNSON (JNJ)'s market cap is 624.3 bn USD.